
邦邦的背包熊🐻
邦邦的背包熊🐻
特别备注: 如果跟我单, 浮亏时禁止加仓,禁止加仓!否则后果很严重很严重! 建议一段时间后退出再重新跟, 避免仓位比例不一致导致的问题 你好,听说过麦门吗? 这里是桂系金拱門哦~ Ba la ba ba ba~欢迎光临麦当当,请自助点单哦~ 十三年 A 股交易经验,具备较丰富盘感与策略体系。 仓位结构上,部分多空双开,部分稳健持仓。 跟单若因滑点未成交,不必纠结;我不会一次打满,错过即错过。 风险敞口合理控制,追求账户长期稳健。
88Following
2.6Kfollowers
Feed
Livestream
Feed
Pinned
Please everyone join my chat room.
Let's discuss market trends together, exchange ideas, and have fun with Maimen.
Welcome to Maimen, Ba la ba ba ba~
I'm waiting for you at the "McDonald's OKX Center".
Our goal is win-win cooperation, allowing all kinds of thoughts and viewpoints to collide here.
Whether you are an expert or a newbie, as long as you love sharing and communicating, you are sincerely welcome to join.
Here, we have:
✅ Sharing of information and technology
✅ Discussion of market trends
✅ A lively and friendly communication atmosphere



#闪迪MSCI调仓生效,NAND估值受关注
for America!for trump !for Jensen! for sndk!
$SNDK


-23.36K
-478.12%Snapshot at Nov 18, 2026, 23:52
Is it okay to buy the dip on SanDisk today?
#闪迪将于11月19日实施1拆8拆股 First, there are many voices in the market believing that SanDisk is currently oversold and can be bought. Let's analyze it first as a risk warning. Viewpoint 1: "It has halved since October, bottom-fishing has potential value" — the direction is correct, but "halving" itself is not a reason to buy.
The stock price has retreated about 74% from the high of $2355 to $749, which is indeed an extreme drop. But Citron's short report in February 2026 already pointed out the core contradiction: the market is pricing a NAND commodity company like an Nvidia-style growth stock. The historical pattern of the NAND industry is a repeated cycle of "boom—oversupply—collapse," and the high gross margin phase is never permanent. When a cyclical stock halves from its peak, its PE may look lower than before the rise because the denominator (earnings) is at the cycle peak. The current TTM PE is 5.84x, Forward PE is 3.26x, which is a typical reading of "peak earnings compressing valuation," and cannot be simply equated with "undervalued." Viewpoint 2: "The trend is closely related to Nvidia, and Nvidia may bottom out today" — the correlation holds, but "bottoming out today" is an unverifiable bet.
SanDisk and Nvidia have a complementary relationship: Nvidia's GPUs drive AI systems, and SanDisk's storage products carry and deliver data; SanDisk is also developing storage solutions for future Nvidia systems. This determines that Nvidia's deployment pace directly determines SanDisk's data center SSD demand. But currently Nvidia is facing
"Triple and Halving: Why the GLP-1 Duopoly Has Shifted from 'Rising Together' to 'Divergence'"
#Novo Nordisk and Eli Lilly $LLY $NVO In September 2023, Eli Lilly and Novo Nordisk were grouped together in the market narrative: GLP-1 is opening up a hundred-billion-dollar metabolic disease market, and the two companies are the "duopoly" in this market; buying either one is equivalent to buying the track itself. Three years later, the same track is still expanding—the US incretin prescription volume still grew 31% year-over-year in Q2 2026—but the stock prices of the two companies have gone to opposite extremes. Eli Lilly rose from about $550 billion market cap to about $1.3 trillion, nearly tripling; Novo Nordisk fell from about $420 billion to about $183 billion, more than halving. The track has not shrunk, nor has it deteriorated. What has changed is the market's answer to the question "who has sustainable competitive advantage in the track." The 2023 pricing logic was "are you in this track or not"; the 2026 pricing logic is "your position in the track, is it structural or temporary." Novo Nordisk has been re-priced as the latter, while Eli Lilly has been confirmed as the former. Market sentiment divergence: from "track premium" to "execution premium" The market sentiment in September 2023 was strongly narrative-driven. Novo Nordisk's market cap surpassed LVMH to become Europe's largest by market cap, Eli Lilly's market cap broke $550 billion, and financial blogs shouted "weight loss drugs are the new AI." At that stage, the market's pricing of the two companies did not require precise distinction of whose efficacy was better or whose pipeline was deeper. GL
What should beginners understand about Anthropic's IPO
#AnthropicIPO Progress: Subscription Orders Nearly 7 Times the Issuance Size On November 19, 2026, Anthropic will debut on Nasdaq under the ticker "ANT." Its IPO subscription orders have reached nearly 7 times the proposed issuance shares, with enthusiasm even surpassing that of SpaceX at the same stage. Based on the upper limit of the $70–78 issuance range, the base offering size is approximately $64.4 billion, combined with a $26 billion private placement, the total fundraising target is up to $90.4 billion, with a fully diluted valuation of about $1.4 trillion. An AI company established only five years ago is about to face public market scrutiny at a valuation in the trillions. For newcomers entering the market, the real question beneath the excitement is just one: what exactly justifies this valuation, and what factors might cause it to fluctuate? 1. Fundamentals: Growth is real, losses are real too Anthropic's revenue curve is indeed steep. In the first nine months of 2026, revenue reached $33.242 billion, with about $17 billion in the third quarter alone, and an annualized revenue run rate exceeding $81 billion. Revenue mainly comes from enterprise API calls and usage-based services, rather than fixed monthly fees from individual subscriptions—this means it sells "intelligence that can participate in productive activities," with customer payment willingness tied to actual usage rather than a mere user scale bubble. But losses are equally notable. In the first nine months, spending on computing power and infrastructure was about $18.8 billion, accounting for 57% of total revenue; GAAP operating loss was about 1
For those trading with me, pay attention to SanDisk's long-short ratio,
Mine is almost 1:1. Just now someone was forcibly liquidated at 770, which is not right.
Need to exit and re-enter.
-18.63K
-340.10%Snapshot at Nov 17, 2026, 18:44
SanDisk, Micron, Hynix, who will be the last to laugh
#The US plans to expand AI chip export restrictions, potentially affecting overseas computing power leasing A comparison of three storage chip companies requires first understanding a structural mismatch: SK Hynix and Micron are IDM giants directly competing in the DRAM/HBM "AI main track," while SanDisk, spun off from Western Digital, is a pure NAND/SSD player with a scale an order of magnitude smaller but has gained a unique revaluation logic in the structural demand for enterprise-grade SSDs. The future market value competition, in the short term, depends on the profit realization and valuation discount repair of HBM; in the medium to long term, it depends on who can occupy a more irreplaceable position in the AI storage chain as it moves from "training" to "inference + data supply." 1. Business DNA: Three distinctly different storage positions SK Hynix is the purest "HBM beneficiary." In fiscal year 2025, revenue was 97.15 trillion KRW (about 68.16 billion USD), net profit 42.95 trillion KRW, net profit margin 44%, a record high. Its core driver comes from HBM—by Q3 2025, Hynix's global HBM market revenue share reached 57%, and it has taken the lead in building an HBM4 mass production system, securing about 70% of Nvidia Rubin platform's HBM4 orders with a yield of about 90%. Hynix is almost entirely focused on storage chips, without Samsung-style diversified business dilution, which gives it the greatest profit elasticity when HBM is on the rise. Micron is an IDM challenger in DRAM+HBM and the only major domestic US storage manufacturer. FY2025 revenue
Lilly: Not Just a Weight Loss Drug
#OKX星球话题来啦 Eli Lilly's moat cannot be simply attributed to "stronger drug efficacy." The deeper barriers are formed by a three-layer structural overlay. The first layer is the engineering barrier at the molecular design level. Tirzepatide is a GIP/GLP-1 dual receptor agonist, and its design is not a simple combination of two agonists. Eli Lilly uses an "unbalanced" design: it maintains strong affinity for the GIP receptor while deliberately weakening binding and activation of the GLP-1 receptor, activating only specific signaling pathways on the GLP-1 receptor without triggering internalization. This fine-tuning allows for higher dosages, thereby amplifying weight loss effects while reducing side effects such as nausea. The "micro-sculpting" of peptides on a single molecule relies on Eli Lilly's manufacturing capabilities accumulated since the insulin era, making it difficult to replicate or surpass in the short term. The second layer is prescription inertia established by clinical evidence. In the SURMOUNT-5 head-to-head trial, tirzepatide achieved an average weight loss of 20.2% over 72 weeks, significantly outperforming semaglutide's 13.7%. In the metabolic disease field, superior head-to-head data have a lasting influence on doctors' prescribing habits—once a drug proves superior in direct comparison, newcomers need evidence at least as strong as head-to-head trials to challenge that position. The third layer is the pipeline relay within the time window. Tirzepatide's core patent is expected to expire around 2032, about six years from now, not "ten years." Eli Lilly's task during this window is to convert tirzepatide's cash flow into the next-generation growth engine. Oral or forglipron
McDonald's (MCD): An undervalued "real estate rent-collecting machine" paying the price for a pricing mistake
#交易之声:你的经验值得被听到 #McDonald's, a 40-year 456-fold investment As of November 13, 2026, McDonald's stock price is about $271.97, with a TTM P/E ratio of 21.34 and a total market value of approximately $192 billion. This valuation is not expensive when placed within McDonald's own historical range — in April 2026, its stock price stood above $310, corresponding to about a 26 P/E ratio. It has dropped about 12% in more than half a year. What the market is really pricing is not that burgers are unsellable, but whether the company has already paid the customer traffic cost for "raising prices too fast" after the pandemic.
1. Valuation and target price: Consensus points to moderate upside, but the divergence lies in "what drives the rise" Currently, Wall Street's consensus on McDonald's is relatively positive. Over the past three months, 25 analysts have given an average target price of $293.48, with a high of $343 and a low of $230; StockAnalysis's aggregated 1-year target price is $299, implying about 10% upside. After the Q3 earnings report in early November, multiple institutions raised their target prices: Citi raised from $295 to $315, Wells Fargo from $270 to $300, Bernstein from $250 to $280, and JPMorgan from $250 to $270. However, between the target price increases and decreases, there is a clear dividing line. JPMorgan's increase is the smallest (only $20) and explicitly anchors its logic on "long-term operations brought by store modernization"






